English
French
Press Release
|
31 |
May 2023 |
IntelGenx Unveils Short-Term Commercial Objectives... |
|
17 |
May 2023 |
IntelGenx Receives Amended DEL License to Conduct Third-Party Testing... |
|
11 |
May 2023 |
IntelGenx Reports First Quarter 2023 Financial Results... |
|
04 |
May 2023 |
IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow... |
|
27 |
Apr 2023 |
IntelGenx Extends Period to Exercise Certain Warrants... |
|
27 |
Apr 2023 |
IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film... |
|
17 |
Apr 2023 |
IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine... |
|
13 |
Apr 2023 |
IntelGenx Announces Organizational Changes to Support Global Growth Strategy... |
|
29 |
Mar 2023 |
IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results... |
|
24 |
Mar 2023 |
IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 20... |
|
23 |
Mar 2023 |
IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 – Conference Call to Follow... |
|
21 |
Mar 2023 |
IntelGenx Announces Closing of Notes Offering... |
|
09 |
Mar 2023 |
IntelGenx to Participate in the 35th Annual Roth Conference... |
|
21 |
Feb 2023 |
IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent... |
|
09 |
Feb 2023 |
IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatme... |
|
23 |
Jan 2023 |
IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries... |
|
09 |
Jan 2023 |
IntelGenx Receives Fourth and Final Loan Tranche from atai... |